Alnylam Pharmaceuticals, Inc. Dossier
Qualitative Analysis
Business overview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is the global pioneer and commercial leader in RNA interference (RNAi) therapeutics. Founded in 2002, the company has successfully transitioned from an R&D-focused innovator to a fully integrated commercial enterprise. Alnylam's proprietary technology platform utilizes small interfering RNA (siRNA) molecules, often conjugated with N-acetylgalactosamine (GalNAc) to target the liver, to silence disease-causing genes. The company's commercial portfolio features six approved medicines available in over 70 countries, led by its blockbuster transthyretin (TTR) amyloidosis franchise comprising AMVUTTRA (vutrisiran) and ONPATTRO (patisiran). Its rare disease portfolio includes GIVLAARI (givosiran) for acute hepatic porphyria and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Five-year strategy centered on global TTR leadership, delivery of at least two transformative medicines beyond TTR with blockbuster potential, expansion to 10 tissue types and more than 40 clinical programs, and disciplined scaling.
Alnylam is supporting AI-enabled detection, real-world evidence generation and coordinated-care programs with Viz.ai, a large California health system and the American Heart Association to identify ATTR-CM earlier and expand treatment access.
Alnylam is combining more than 20 years of proprietary siRNA data and its RNAi platform with Inceptive's biological foundation models to improve candidate design, prioritization and experimental productivity.
Alnylam entered an exclusive agreement with BeOne Medicines to commercialize AMVUTTRA in mainland China and Macao, extending the geographic reach of its principal TTR product.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Combines Alnylam's proprietary siRNA data and RNAi expertise with generative biological models intended to accelerate discovery and improve oligonucleotide design.
Terms: $30 million of upfront consideration, including cash and an equity purchase, with total potential value of up to $2 billion through preclinical, regulatory and commercial-sales milestones.
The partners are developing an ATTR-CM care pathway and conducting the AWARE implementation study across five pilot health systems to support earlier diagnosis and scalable clinical adoption.
Provides a partner-based route to broaden AMVUTTRA's reach in China following the required marketing authorization.
The collaboration supports the approximately 11,000-patient ZENITH Phase 3 cardiovascular-outcomes study and gives Alnylam access to Roche's global development and commercialization capabilities.
Terms: Alnylam received $310 million upfront and may receive up to $2.8 billion in total deal value. The companies share U.S. profits and losses equally; Roche has exclusive ex-U.S. commercialization rights with low-double-digit royalties to Alnylam. Development costs are shared 40% by Alnylam and 60% by Roche. First dosing in ZENITH triggered a $300 million milestone in 2025.
The collaboration extends Alnylam's platform into generalized myasthenia gravis, Huntington's disease, Alzheimer's disease and tauopathies; cemdisiran applications have been accepted in the United States and Europe.